Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
Pathos assumes responsibility for early clinical development of AZD4241, utilizing its AI-driven Foundry platform to drive patient stratification and t...
SCIEX, a Danaher company and leader in life science analytical technologies, announced new solutions designed to help clinical laboratories move from sam...
Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase 1 clinical study evaluating B...
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to...
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding ...
Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, announced the expansion of its mu...
In a significant move to advance the treatment of patients with inflammatory breast cancer (IBC), Dana-Farber Cancer Institute, The Ohio State Univ...
-Crown Bioscience is a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced it has joined...
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational chemistry company focused on the generative design of small molecules for the pharmaceuti...
Abcam, a Danaher company and a global provider of validated antibodies and assay solutions, and EpiCypher®, the leading provider of ChIC/CU...
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Diva...
Neurocrine Biosciences, Inc. announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in ...
Corten Capital and Ampersand Capital Partners (“Ampersand”) are pleased to announce the completion of their acquisition of Beacon Intelligenc...
© 2026 Biopharma Boardroom. All Rights Reserved.
